Brown-Forman BF-B
Consumer Defensive · Beverages - Wineries & Distilleries · Synthos Deep Dive · 2026-07-03
The Overview
Brown-Forman is the company behind Jack Daniel's whiskey — plus Woodford Reserve, Herradura and el Jimador tequila, and a growing line of pre-mixed canned cocktails. It has paid a dividend every quarter for 82 straight years and raised it for 42 years running, which tells you this is a steady, conservative, old-money business.
The problem: people are drinking a little less, especially in the US, and the whiskey and tequila categories have gone soft. So sales actually shrank last year and profit fell. The stock isn't wildly expensive — you're paying about 17 dollars for every dollar of yearly profit, which is fair — but there's no obvious reason for it to jump, because the business itself isn't growing right now. Our verdict is Watch: a fine, safe dividend-payer to keep an eye on, but not something to rush into for big gains.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). The dividend is rock-solid and the stock barely moves day to day, but the whole industry is drifting the wrong way, and this stock has lost two-thirds of its value from its old peak.
- Growth Quality 3/10 (weak). The company is very profitable, but it's basically not growing — sales went backwards last year.
- Exponential Potential 1/10 (almost none). This is a slow, mature company in a shrinking market. Do not expect it to multiply your money.
The one big worry: fewer people are drinking spirits, and Brown-Forman doesn't have a fast-growing new product big enough to make up for it.
Putting a number on it: our fair-value estimate is $28 against a current price of $27.22 — real upside if our numbers are right.
Our summary metrics
Fortress brand & 3.5% aristocrat dividend, low 0.34 beta — but a shrinking spirits market, tariff/tequila drag, and a −68% historical drawdown.
~4% forward revenue and ~6% EPS CAGR off a declining FY26; 60.5% gross margin and 18% ROE are high, but the top line is going sideways.
Mature, decelerating, whiskey-concentrated staple in a secularly softening category — no acceleration and no room-to-run optionality.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature, decelerating, whiskey-concentrated staple in a secularly softening category — no acceleration and no room-to-run optionality.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | No numeric price target on file; grades consensus = Hold (0 Strong Buy · 5 Buy · 24 Hold · 7 Sell) — context, not our anchor |
| Valuation | 17.2× trailing EPS · ~15× FY27E · ~14× FY30E · EV/S 3.6× · EV/EBITDA 13.3× |
| Technicals | Downtrend — $26.15, −16% off the 52-wk high, below 50/200-DMA, RSI 46, −6% 12-mo vs SPY +21% |
| Conviction | Low — 0 expert voices, 0 KB claims; call rests entirely on fundamentals + quant |
| Position sizing | Income/defensive satellite only, ~1–2% if owned at all — for the yield, not the growth |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for BF-B — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $27.22, 0% below the 50-day average ($27), 0% below the 200-day average ($27) — a downtrend. 12% below the 52-week high of $31, 19% above the 52-week low of $23.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $27.22 is currently inside the band (band $27–$29).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 45.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.16, negative momentum.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = BF-B · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Brown-Forman (NYSE: BF-B) is a ~155-year-old, family-controlled (Brown family) global spirits maker headquartered in Louisville, Kentucky. Its fiscal year ends April 30. The crown jewel is the Jack Daniel's family of Tennessee whiskeys; the portfolio also includes Woodford Reserve, Old Forester, Herradura and el Jimador tequila, New Mix (a fast-growing Mexican RTD), Gin Mare, Diplomático rum, and Chambord. The company sells through independent distributors and, in control states, state governments.
It is a member of the S&P 500 Dividend Aristocrats — 82 consecutive years of quarterly dividends and 42 consecutive years of increases.
Revenue mix (FY2026, from filings):
- By product: Whiskey $2.90B (~74%) · Ready-to-Drink $542M (~14%) · Tequila $251M (~6%) · Rest of portfolio $201M · Non-branded & bulk $33M. The business is heavily concentrated in whiskey, and within whiskey, in Jack Daniel's — a strength (brand power) and a concentration risk.
- By geography: United States $1.65B (~42%) · Other Countries $1.35B · Mexico $319M · Germany $248M · Australia $200M · UK $164M. US revenue fell to $1.65B in FY26 (from $1.77B FY25), while Emerging markets and Travel Retail grew — the geographic mix is shifting away from a soft US.
The strategic story management keeps returning to (see §9) is a US route-to-market transformation (changing distributor terms), a cost-restructuring program (announced Jan 2025), and innovation — chiefly Jack Daniel's Tennessee Blackberry and the New Mix RTD line — to offset a declining core.
2. The expert thesis — why the panel is (not) covering it (traceable)
There is no expert coverage of Brown-Forman in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. No independent voice we track — bullish or bearish — has published a traceable claim on this name.
That is itself a signal: the panels Synthos ingests skew toward technology, AI, biotech, and high-growth compounders, and a mature consumer-staples spirits maker simply does not come up. We will not manufacture conviction we do not have. Everything below is therefore driven by the fundamentals (FMP filings), the analyst-estimate consensus, management's own guidance (half-weighted), and quant — not by expert conviction. Treat the verdict accordingly: it is a disciplined read of the numbers, not a high-conviction call backed by a panel.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Net-debt/EBITDA 1.75×, beta 0.34, a 3.5% aristocrat dividend and 60.5% gross margin cushion the downside — but the top line is shrinking, the category is softening, tariffs/tequila are a drag, and the stock has a −68% historical peak-to-trough drawdown. Cheap-ish (17×) limits the de-rating risk. |
| Growth Quality | 3 · Weak | 18% ROE and 60.5% gross margin are genuinely high-quality, but FY26 revenue fell 1% and EPS fell 17%; forward revenue CAGR is only ~4% and EPS ~6% off a depressed base. Profitability is good; growth is not. |
| Exponential Potential | 1 · Very Low | Mature, whiskey-concentrated staple in a secularly softening category; growth is flat-to-negative with no acceleration and a $12B cap in a slow TAM. Nothing here points to a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Restructuring + US distributor changes take hold, RTD (New Mix, +33% organic) and emerging markets re-accelerate the top line to low-single-digit growth; FY27E EPS recovers to ~$1.80 and the market re-rates a stabilizing aristocrat to ~22×. | ~$39 (+49%) |
| Base (our anchor) | FY27 plays out roughly as guided — organic sales ~flat, operating income down low-single-digits — then a slow recovery; FY27E EPS ~$1.70, a durable but low-growth aristocrat earns a ~16× multiple. | ~$28 (+7%) |
| Bear | The spirits down-cycle deepens, US tariffs and Canadian delisting persist, tequila keeps sliding; FY27E EPS slips toward ~$1.55 and the multiple de-rates to ~14× as growth stays absent. | ~$21 (−20%) |
Synthos fair value = the base case, ~$28 (+7%), with the full $21–$39 span as the honest range. There is no numeric Street price-target on file; the analyst grades consensus is Hold (5 Buy / 24 Hold / 7 Sell), which squares with our Watch. This is a tracked call — the Forecaster Scorecard grades it once it matures. The modest ~7% base-case upside plus a 3.5% dividend is a total-return-ish proposition, not a capital-appreciation thesis.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). BF-B is neither right now — it is a high-quality but currently shrinking staple:
- Forward growth: revenue CAGR FY26→FY31E ~4.2% ($3.93B → $4.82B est); EPS CAGR FY26→FY30E ~6% ($1.53 → $1.93 est) — and that "growth" is largely recovery off a down year, not expansion.
- Acceleration (the 2nd derivative) is flat-to-negative: revenue −1% (FY26), guided ~flat organic (FY27), then low-single-digit. There is no inflection; management itself guides operating income down 3–5% next year.
- Room to run: the global spirits TAM is large but mature and softening; a $12B-cap aristocrat in a low-growth category has no realistic path to a multibagger from demand alone.
- Optionality: the only genuine bright spots are the RTD line (New Mix +33% organic, +41% reported) and emerging markets (+12% organic) — real but small relative to a $2.9B whiskey base that is barely growing.
Exponential Potential: Very Low (1/10). Own BF-B, if at all, for the dividend and brand durability, never for growth. This honest framing is why it lands in Watch, not any Buy tier.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY26 $3.93B, −1.2% (FY25 $3.98B, itself −4.9% on FY24 $4.18B). The top line has now declined two years running off the FY23 $4.23B peak. Flat-to-down at scale.
- Quarterly trajectory: FY26 by quarter — Q1 $924M → Q2 $1,036M → Q3 $1,056M → Q4 $912M (+2% reported YoY). Seasonal (fiscal Q3 is the holiday peak); no clear acceleration.
- Margins: gross 60.5% TTM (expanded 160 bps in FY26 on mix/divestitures), EBIT ~25% (operating margin fell 240 bps to 25.5% on impairments and higher SG&A), net 18.2% TTM. Profitability is strong and mostly holding.
- Earnings: net income $715M FY26, down from $869M FY25 and $1,024M FY24; diluted EPS $1.53 (−17%), hit by lower operating income and the absence of a prior-year Duckhorn gain.
- Cash flow: the FY26 bright spot — operating CF grew $402M to $1.0B, and free cash flow rose $462M to $893M (FCF yield ~7.3%) on working-capital discipline and lower capex. FCF now exceeds net income (income quality 1.4×).
- Balance sheet: total debt $2.15B, cash $308M, net debt ~$1.84B, net-debt/EBITDA ~1.75× — investment-grade (letter rating A-), comfortably serviceable against ~$1.1B EBITDA; interest coverage ~11×.
- Capital return: returned $827M to holders in FY26 ($427M dividends + $400M buyback, completed Dec 2025).
6. Valuation — priced in or room?
BF-B is not expensive on trailing numbers (17.2× EPS, 3.6× EV/sales, 13.3× EV/EBITDA, ~7.3% FCF yield, 3.5% dividend yield) — well below its own historical premium (this stock has traded 25–35× for much of the past decade). The catch is why it's cheaper: there is almost no earnings growth to discount. On consensus, forward P/E is ~15× (FY27E $1.70) easing to ~14× (FY30E $1.93) — the multiple barely compresses because EPS barely grows. FMP's letter rating is A- (quality) but flags a full price-to-book (~3.0×). A reverse read: at ~17× trailing with flat-to-low-single-digit growth, the stock is priced roughly fairly for a stable aristocrat — cheap enough to limit downside, not cheap enough to be a value bargain, and lacking the growth to be a growth buy. Street targets (context): no numeric consensus target on file; the grades split (5 Buy / 24 Hold / 7 Sell) reads Hold. Our $28 base-case FV (+7%) sits modestly above the current price — a hold-for-the-yield, not a table-pound.
7. Technicals (from the tech block)
- Trend: down. $26.15 sits below the 50-DMA ($26.49) and the 200-DMA ($27.30), and the 50 is below the 200 (death-cross posture). MACD marginally positive (+0.12) — no confirmed turn.
- Location: −16.3% off the 52-week high ($31.26), +14.7% off the 52-week low ($22.80). The max drawdown from peak is −68% — a reminder of how far this has fallen from its 2021–22 highs.
- Momentum: RSI(14) 46 — neutral, neither oversold nor overbought; no technical entry signal either way.
- Relative strength (the tell): BF-B −6.1% 12-mo vs SPY +20.6% and QQQ +30.3%; −1.3% 3-mo vs SPY +13.7%. Persistent underperformance of both the market and growth.
- Read: technicals do not confirm a turn — a below-trend, relatively weak chart. No urgency to buy; if owned for income, a base near the 52-week low / rising dividend support is the level to watch. Wait for the top line to stop shrinking before pressing.
8. Moat & competitive position
Brown-Forman's moat is brand and heritage: Jack Daniel's is one of the most valuable spirits trademarks in the world, aged-whiskey inventory (2–8 years) is a genuine barrier (598 days of inventory outstanding — a working-capital cost and a moat), and family control (Brown family voting shares) gives long-horizon stability. The weakness is the flip side of concentration: ~74% of sales are whiskey, so a soft US whiskey cycle hits disproportionately, and tequila (Herradura −10% organic) is also sliding.
Peer set (FMP-supplied; note it is a broad consumer-staples group, not pure spirits comps): Molson Coors (TAP) $7.5B, Coca-Cola Consolidated (COKE) $15.4B, Clorox (CLX) $11.8B, Hormel (HRL) $13.8B, J.M. Smucker (SJM) $12.4B, Campbell (CPB) $7.0B, plus grocers/distributors (ACI, BJ, PFGC). The truest public comps (Diageo, Pernod Ricard, Constellation) aren't in this list; against them BF-B carries a premium brand and margin profile but the same category headwind. Relative to the staples peers shown, BF-B has a higher gross margin (60.5%) and stronger brand equity, but weaker current growth.
9. Management, capital allocation & guidance
- Capital allocation: conservative and shareholder-friendly — $827M returned in FY26 ($427M dividends + $400M buyback), a 42-year dividend-increase streak, net-debt/EBITDA held ~1.75×. The FY26 focus was cash generation (FCF +$462M) in a down market — disciplined stewardship.
- Insider activity: the sampled Form 4s (all dated 2026-05-27/29) are routine equity awards and tax-withholding in-kind dispositions to officers (EVP-level grants at $0 and F-InKind at $25.94) — compensation mechanics, no discretionary open-market selling or buying signal in the window.
- Management's own guidance — FY2027 outlook (from the 2026-06-04 SEC 8-K / earnings release; this is management's own, self-interested framing — half-weighted):
- Organic net sales: approximately flat.
- Organic operating income: decline of 3% to 5%.
- Effective tax rate: ~20–22%.
- Capex: $60–70M (down sharply — a lever behind rising FCF).
- CEO Lawson Whiting: finished FY26 "ahead of our expectations," expects "continued market volatility and a challenging cost cycle in the year ahead," leaning on the restructuring program (announced Jan 2025), the US route-to-market transformation, and innovation (Jack Daniel's Tennessee Blackberry, New Mix RTD). Read honestly: management is guiding to another down-ish year on operating income — the numbers, not the tone, are the signal.
10. Catalysts & what to watch
- Next earnings: 2026-08-27 (Q1'27; Street EPS $0.37, revenue ~$918M). Watch organic net sales (is the top line stabilizing?) and US trends post distributor-term changes.
- US route-to-market transformation & restructuring: early-benefit realization is management's core FY27 story — watch for it in operating margin.
- RTD & emerging markets: New Mix (+33% organic) and emerging-market growth (+12%) are the offsets to a soft core — do they scale?
- Tequila stabilization: Herradura/el Jimador have been weak; a turn would matter to mix.
- Tariffs & Canada: the absence of American-made spirits from most Canadian provincial shelves, and US/EU tariff dynamics, are live external risks.
- Dividend action: the annual raise (streak now 42 years) is the income investor's key tell of board confidence.
Thesis tripwires (what would change the call): two more quarters of organic-sales decline (bearish); or, on the upside, a return to sustained low-single-digit organic growth plus margin recovery (would push toward Buy — Tactical); a dividend-growth pause would be a serious red flag.
11. Key risks
- Secular category softness (structural): spirits — especially US whiskey and tequila — consumption is soft; BF-B's ~74% whiskey concentration amplifies it. No large offsetting growth engine yet.
- No growth catalyst / value-trap risk: cheap-ish at 17×, but "cheap and not growing" can stay cheap; the ~7% base-case upside is thin.
- Tariffs & trade: US/EU tariff exposure and the Canadian provincial delisting of American spirits directly hit sales and mix.
- Concentration: Jack Daniel's dominates; any brand-specific stumble (or a shift in whiskey preference) is outsized.
- FX & emerging-market volatility: a growing share of the offset comes from Mexico/emerging markets, adding currency and macro risk.
- No expert coverage: unlike our conviction names, there is zero KB breadth here — the call has no independent-panel corroboration, so treat the confidence as correspondingly lower.
12. Verdict, position sizing & monitoring
Watch. Brown-Forman is a genuinely high-quality, family-controlled dividend aristocrat with a fortress brand (Jack Daniel's), a 60.5% gross margin, rising free cash flow (+$462M to $893M in FY26), and a fair-ish ~17× multiple. But the top line shrank in FY26 (revenue −1%, EPS −17%), management guides FY27 organic operating income down 3–5%, the chart is in a relative-weakness downtrend, and there is no expert conviction and no growth catalyst to underwrite an upgrade. The base case is ~$28 (+7%) plus a 3.5% dividend — a respectable income outcome, not a compelling appreciation one.
- Sizing: if owned at all, an income/defensive satellite at ~1–2% — for the yield and stability, not for growth. Not a core-growth holding.
- Monitoring: re-underwrite on the §10 tripwires; a return to sustained organic growth would move it toward Buy — Tactical, while a second leg down in sales (or any dividend-growth pause) would move it toward Avoid. Formal re-score each earnings print.
- Single biggest risk: a structurally softening spirits market — especially US whiskey and tequila — with no offsetting growth engine large enough to matter.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $26.15.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage of BF-B in the Synthos knowledge base. The verdict is explicitly fundamentals- and quant-driven; no conviction is claimed or implied. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here there are simply no claims to cite.
- Data as-of: fundamentals FY26 (year ended 2026-04-30) · estimates & prices 2026-07-02/03 · management guidance from the 2026-06-04 SEC 8-K (Item 2.02) earnings release. Forward figures are analyst consensus (FMP) or management guidance, each labeled as estimates.
- Management caveat: the FY27 outlook in §9 is management's own, self-interested framing, half-weighted by design.
- Street note: no numeric price-target consensus was available on file; the analyst grades split (5 Buy / 24 Hold / 7 Sell = Hold) is shown as context, not as our anchor.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").